The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Dysfunctional synapse in Alzheimer's disease – A focus on NMDA receptors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Tripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“In fact, astrocytes may respond to neuronal activity through an elevation of internal Ca 2+ concentration, which further leads to the release of neurotransmitters able to cause feedback regulation of neuronal activity and synaptic efficacy (Araque et al., 1999).”
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
MacDermott, A. B., Mayer, M. L., Westbrook, G. L., Smith, S. J., & Barker, J. L. (1986) · Nature · doi:10.1038/321519a0 · Cited by 1,835
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686 · cited 1×
“…factor (BDNF) gene ), whereas activation of extrasynaptic NMDARs activated a general and dominant CREB shut-off pathway (Kaufman et al., 2012;Hardingham et al., 2002); this effect could be prevented by the use of memantine (Kaufman et al., 2012), commonly used as AD treatment, and which…”
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644 · cited 3×
“Interestingly, extrasynaptic NMDARs have been largely associated with NMDARs excitotoxicity in AD (Hardingham and Bading, 2010).”
InfluentialShankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 1×
“Moreover, treatment of rat organotypic slices containing pyramidal neurons with Aβ oligomers decreased dendritic spine density and reduced NMDAR-mediated Ca 2+ influx (Shankar et al., 2007).”
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1×
“On the other hand, the decrease in NMDAR subunits may also be due to an increase in STEP 61 , which contributes to the endocytosis of GluN1/GluN2B and GluN1/GluN2A receptors (Snyder et al., 2005;Kurup et al., 2010).”
De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · cited 1×
“Thus, inter alia, in mature hippocampal neurons memantine was shown to prevent oligomeric Aβ-induced oxidative stress (De Felice et al., 2007) as well as the disruption of axonal transport trafficking (Decker et al., 2010), DNA fragmentation, microtubule deregulation and neurite retraction (Mota et…”
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Liu, Y., Wong, T. P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T. W., Wu, D. C., Lu, J., Tymianski, M., Craig, A. M., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0116-07.2007 · Cited by 773 · cited 1×
“Since GluN2A subunits have been implicated in protective pathways, whereas GluN2B subunits appear to increase neuronal vulnerability (Liu et al., 2007), the early increase in GluN2A and decrease in GluN2B subunit-composed NMDARs activity may be an attempt to reduce Aβ-induced neuronal dysfunction.”
Oxidative stress in the progression of Alzheimer disease in the frontal cortex
Ansari, M. A., & Scheff, S. W. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181cb5af4 · Cited by 605 · cited 1×
“In AD patients, oxidative stress markers were demonstrated to correlate with Mini-Mental Status Examination scores; importantly, oxidative stress was more localized to the synapses, with levels increasing in a disease-dependent manner (Ansari and Scheff, 2010).”
Glial cells in (patho)physiology
Parpura, V., Heneka, M. T., Montana, V., Oliet, S. H. R., Schousboe, A., Haydon, P. G., Stout, R. F., Spray, D. C., Reichenbach, A., Pannicke, T., et al. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07664.x · Cited by 561 · cited 2×
“Astroglial NMDARs, shown to be present in the cortex and the spinal cord, are characterized by weak Mg 2+ block and moderate Ca 2+ permeability (reviewed by Parpura et al., 2012)).”
Jacob, C. P., Koutsilieri, E., Bartl, J., Neuen-Jacob, E., Arzberger, T., Zander, N., Ravid, R., Roggendorf, W., Riederer, P., & Grünblatt, E. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11113 · Cited by 317
Mg2+Imparts NMDA Receptor Subtype Selectivity to the Alzheimer's Drug Memantine
Kotermanski, S. E., & Johnson, J. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3703-08.2009 · Cited by 271
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266 · cited 2×
“Thus, when patients receiving only ACh-esterase inhibitors are compared with patients receiving the same treatment plus memantine, the ability for M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 24 independence, a factor that reflects cognitive capacity, is increased (Lopez et al., 2009).”
NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation
Amadoro, G., Ciotti, M. T., Costanzi, M., Cestari, V., Calissano, P., & Canu, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511065103 · Cited by 243
Groc, L., Choquet, D., Stephenson, F. A., Verrier, D., Manzoni, O. J., & Chavis, P. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1772-07.2007 · Cited by 225 · cited 1×
“Therefore, reelin inhibition was shown to decrease GluN2B subunit availability at the synapse (Groc et al., 2007).”
Fox, C., Crugel, M., Maidment, I., Auestad, B. H., Coulton, S., Treloar, A., Ballard, C., Boustani, M., Katona, C., & Livingston, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035185 · Cited by 173
A Phenotypic Change But Not Proliferation Underlies Glial Responses in Alzheimer Disease
Serrano-Pozo, A., Gómez-Isla, T., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.02.031 · Cited by 169 · cited 1×
“…were observed and remained constant over the clinical course of the disease, suggesting that phenotypic change of existing glial cells, rather than a marked proliferation of glial precursors, accounts for by the majority of glial responses observed in the AD brain (Serrano-Pozo et al., 2013).”
Rammes, G., Hasenjäger, A., Sroka-Saidi, K., Deussing, J. M., & Parsons, C. G. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.051 · Cited by 163 · cited 2×
“…coupled to postsynaptic NMDARs, with low concentration of allosteric antagonist (MPEP, 2-methyl-6-(phenylethynyl)-pyridine) prevent Aβ oligomers-induced LTP impairment (Rammes et al., 2011), evidencing that the glutamatergic system may be considered as a target for the development of AD drugs.”
Mishizen-Eberz, A. J., Rissman, R. A., Carter, T. L., Ikonomovic, M. D., Wolfe, B. B., & Armstrong, D. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.016 · Cited by 156 · cited 2×
“Conversely, other studies evidenced that mRNA levels of GluN1 (Bi ) and GluN2A subunits (Mishizen-Eberz et al., 2004) were unchanged in AD patient's brains.”
Regulation of NMDA receptor Ca2+ signalling and synaptic plasticity
Lau, C. G., Takeuchi, K., Rodenas-Ruano, A., Takayasu, Y., Murphy, J., Bennett, M. V. L., & Zukin, R. S. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371369 · Cited by 138
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126 · cited 1×
“…AD patients the co-treatment significantly increased cognition, function and global status when compared to donepezil-treated patients and reduced rates of marked clinical worsening (Atri et al., 2013), and also improved measures of activities of daily living and behavior (Tariot et al., 2004).”
Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex
Henson, M. A., Roberts, A. C., Salimi, K., Vadlamudi, S., Hamer, R. M., Gilmore, J. H., Jarskog, L. F., & Philpot, B. D. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhn017 · Cited by 110 · cited 1×
“In humans, GluN1 levels are low in embryonic prefrontal cortex and increases after birth (Henson et al., 2008), remaining constant with age in whole brain (Law et al., 2003).”
Reelin depletion is an early phenomenon of Alzheimer's pathology
Herring, A., Donath, A., Steiner, K. M., Widera, M. P., Hamzehian, S., Kanakis, D., Kölble, K., ElAli, A., Hermann, D. M., Paulus, W., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-112069 · Cited by 92 · cited 1×
“Additionally to a decrease in mRNA levels, the decrease in GluN2B and GluN2A subunits could be due also to a decrease in reelin levels, a protein that mediates NMDAR activity, and which is depleted in AD brains (Herring et al., 2012).”
GlutamateNMDA receptor NR1 subunit mRNA expression in Alzheimer's disease
Hynd, M. R., Scott, H. L., & Dodd, P. R. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00409.x · Cited by 66
Cited by
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
The Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535
González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D., & Mora-Muñoz, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00427 · Cited by 527
Costa, L. G., Cole, T. B., Dao, K., Chang, Y.-C., Coburn, J., & Garrick, J. M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107523 · Cited by 484
Calcium signaling and molecular mechanisms underlying neurodegenerative diseases
Pchitskaya, E., Popugaeva, E., & Bezprozvanny, I. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.06.008 · Cited by 349
Metadata
- Authors
- Mota, S. I., Ferreira, I. L., & Rego, A. C.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 76
- Pages
- 16-26
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2052712042
- Cited by
- 206
- References
- 27
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.